Biopharmaceutical Company Atossa Genetics Receives Buy Rating from H.C. Wainwright, Sets New Price Target at $4.00
Biopharmaceutical company Atossa Genetics received a Buy rating from H.C. Wainwright on Monday, with a new price target set at $4.00. The company is recognized for its promising pipeline centered around Z-endoxifen, an active metabolite of the drug tamoxifen.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
